Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 17/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222946 | 0.92 | CCR5 (0.54) | CCR5KCNH2CYP2D6KCNJ1 | |
| SCHEMBL5221348 | 0.89 | CCR5 (0.55) | CCR5KCNH2CYP2D6 | |
| SCHEMBL5222205 | 0.88 | CCR5 (0.55) | CCR5KCNH2CYP2D6 | |
| SCHEMBL5219147 | 0.84 | CCR5 (0.60) | CCR5KCNH2CYP2D6 | |
| SCHEMBL5220551 | 0.83 | CCR5 (0.61) | CCR5KCNH2CYP2D6 | |
| SCHEMBL5218332 | 0.82 | CCR5 (0.49) | CCR5KCNH2CYP2D6KCNJ1 | |
| SCHEMBL5219971 | 0.81 | CCR5 (0.60) | CCR5KCNH2CYP2D6 | |
| SCHEMBL5221867 | 0.80 | CCR5 (0.56) | CCR5KCNH2CYP2D6 | |
| SCHEMBL3303563 | 0.80 | CCR5 (0.59) | CCR5KCNH2CYP2D6 | |
| SCHEMBL5218446 | 0.79 | CCR5 (0.57) | CCR5KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | ASTRAZENECA AB (SE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | ASTRAZENECA AB (SE) | 2007-05-17 | — | — | US | disclosed |
| EP-1654229-B1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1654229-A1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005009959-A1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | CCR5, CCR2, CCR6 | CCR5 1/4885KCNH2 2301/4885CYP2D6 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.